Skip to main content
Tevogen Bio Holdings Inc. logo

Tevogen Bio Holdings Inc. — Investor Relations & Filings

Ticker · TVGN ISIN · US88165K1016 US Professional, scientific and technical activities
Open in API
Filings indexed 269 across all filing types
Latest filing 2023-03-29 Delisting Announcement
Country US United States of America
Listing US TVGN

About Tevogen Bio Holdings Inc.

https://tevogen.com/

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies. The company utilizes its proprietary ExacTcell™ technology platform to harness the therapeutic potential of CD8+ cytotoxic T lymphocytes (CTLs), a key component of the natural immune system. This platform is designed to create treatments that specifically target antigens present only on diseased cells, thereby preserving healthy tissue and enhancing safety through the use of naturally occurring T cell receptors. The company's development pipeline addresses significant unmet medical needs across multiple therapeutic areas, including oncology, virology, and neurology, with a stated goal of providing affordable and accessible personalized therapies to large patient populations.

Recent filings

Filing Released Lang Actions
FORM 8-K
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 29, 2023, reporting a notice from Nasdaq regarding non-payment of fees and potential delisting of the company's shares. The key content is about a delisting notice and the company's response to it. There are no financial statements or detailed financial data, nor is it an announcement of a report publication. The document fits the definition of a Delisting Announcement (DLST) as it officially notifies about the company's stock potentially being removed from Nasdaq due to non-payment of fees.
2023-03-29 English
Director's Dealing 2023
Director's Dealing
2023-02-16 English
FORM SC 13G/A
Major Shareholding Notification
2023-02-14 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-02-10 English
SC 13D/A
Major Shareholding Notification
2023-02-10 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about an extraordinary general meeting (EGM) where shareholders approved a Charter Amendment extending the deadline for an initial business combination. It also reports the voting results of the EGM and redemption of shares by public shareholders. The document includes no detailed financial statements or comprehensive financial analysis, but rather announcements of corporate actions and voting outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official shareholder vote results and related corporate governance actions. The document length (6620 characters) and content confirm it is not a full annual or quarterly report, nor a simple announcement of a report publication. Therefore, the best classification is DVA with high confidence.
2023-02-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.